2-(甲硫基)-5-丙基-4(3H)-嘧啶酮 | 60902-60-5

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 中文名称: 2-(甲硫基)-5-丙基-4(3H)-嘧啶酮
• 英文名称: 2-(methylthio)-5-propylpyrimidin-4-ol
• 英文别名: 2-methylsulfanyl-5-propyl-1H-pyrimidin-6-one
• CAS: 60902-60-5
• 化学式: C₈H₁₂N₂OS
• 分子量: 184.262
• InChiKey: XZSBYOPGQZIWKD-UHFFFAOYSA-N

物化性质

• 熔点：
  153 °C(Solv: ethanol (64-17-5))
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  2-(甲硫基)-5-丙基-4(3H)-嘧啶酮 在 硫酸氢铵 、 三氟甲磺酸三甲基硅酯 、 氨 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 3.0h， 生成 1-((2R,3R,4S,5R)-3,4-Dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-2-methylsulfanyl-5-propyl-1H-pyrimidin-4-one
  参考文献：
  名称：

  Synthesis of S2-Alkyl-2-thiouridines

  摘要：

  5-取代的S 2-烷基-2-硫脲嘧啶1a-i与1,1,1,3,3,3-六甲基二硅氮烷和硫酸铵在回流温度下反应，然后在乙腈中与1,2,3,5-四-O-乙酰基-β-D-核呋喃糖缩合，使用三甲基硅基三氟甲磺酸作为催化剂，得到相应的保护核苷2a-i，这些核苷随后用甲醇中的饱和氨进行去保护。当核碱基在5位上被乙氧羰基或氰基取代或不取代时，核苷的去保护反应也会导致甲硫基团的替换。对于5-烷基和5-甲氧基取代基，则没有观察到这种现象。

  DOI：

  10.1055/s-1996-4187
• 作为产物：
  描述：

  戊酸甲酯 在 sodium methylate 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 21.0h， 生成 2-(甲硫基)-5-丙基-4(3H)-嘧啶酮
  参考文献：
  名称：

  Original 2-(3-Alkoxy-1H-pyrazol-1-yl)pyrimidine Derivatives as Inhibitors of Human Dihydroorotate Dehydrogenase (DHODH)

  摘要：

  From a research program aimed at the design of new chemical entities followed by extensive screening on various models of infectious diseases, an original series of 2-(3-alkoxy-1H-pyrazol-1-yl)pyrimidines endowed with notable antiviral properties were found. Using a whole cell measles virus replication assay, we describe here some aspects of the iterative process that, from 2-(4-benzyl-3-ethoxy-5-methyl-1H-pyrazol-1-yl)pyrimidine, led to 2-(4-(2,6-difluorophenoxy)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)-5-ethylpyrimidine and a 4000-fold improvement of antiviral activity with a subnanomolar level of inhibition. Moreover, recent precedents in the literature describing antiviral derivatives acting at the level of the de novo pyrimidine biosynthetic pathway led us to determine that the mode of action of this series is based on the inhibition of the cellular dihydroorotate dehydrogenase (DHODH), the fourth enzyme of this pathway. Biochemical studies with recombinant human DHODH led us to measure IC50 as low as 13 nM for the best example of this original series when using 2,3-dimethoxy-5-methyl-6-(3-methyl-2-butenyl)-1,4-benzoquinone (coenzyme Q(1)) as a surrogate for coenzyme Q(10), the cofactor of this enzyme.

  DOI：

  10.1021/jm501446r

文献信息

• H2-Antihistaminika, 18. Mitt. 5,6-Alkylsubstituierte 4-Pyrimidinone mit H2-antihistaminischer Wirkung
  作者：Jan-Peter Spengler、Walter Schunack

  DOI：10.1002/ardp.19843170509

  日期：——

  5,6‐Alkylsubstituierte 2‐2‐[(5‐Methyl‐4‐imidazolyl)‐methylthio]‐ethylamino}‐4‐pyrimidinone wurden dargestellt und auf ihre H2‐antihistaminische Wirksamkeit untersucht.

  制备了 5,6-烷基取代的 2-2-[(5-甲基-4-咪唑基)-甲硫基]-乙氨基}-4-嘧啶酮并检查了它们的 H2-抗组胺活性。
• Pyrazole derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors
  申请人：INSTITUT PASTEUR

  公开号：EP2929883A1

  公开（公告）日：2015-10-14

  The present invention relates to compounds of formula (I) for their use in the treatment and/or prevention of auto-immune or auto-immune related diseases, cancer, viral infections, and central nervous system diseases and disorders, by inhibiting human dehydroorate dehydrogenase (DHODH): Wherein R1, R2, R3, R4 and Ar are as defined in claim 1.

  本发明涉及式（I）化合物，通过抑制人脱氢脱氢酶（DHODH），用于治疗和/或预防自身免疫或自身免疫相关疾病、癌症、病毒感染以及中枢神经系统疾病和失调： 其中 R1、R2、R3、R4 和 Ar 如权利要求 1 所定义。
• SPENGLER, J. P.;SCHUNACK, W., ARCH. PHARM., 1984, 317, N 5, 425-430
  作者：SPENGLER, J. P.、SCHUNACK, W.

  DOI：——

  日期：——
• Original 2-(3-Alkoxy-1<i>H</i>-pyrazol-1-yl)pyrimidine Derivatives as Inhibitors of Human Dihydroorotate Dehydrogenase (DHODH)
  作者：Hélène Munier-Lehmann、Marianne Lucas-Hourani、Sandrine Guillou、Olivier Helynck、Gigliola Zanghi、Anne Noel、Frédéric Tangy、Pierre-Olivier Vidalain、Yves L. Janin

  DOI：10.1021/jm501446r

  日期：2015.1.22

  From a research program aimed at the design of new chemical entities followed by extensive screening on various models of infectious diseases, an original series of 2-(3-alkoxy-1H-pyrazol-1-yl)pyrimidines endowed with notable antiviral properties were found. Using a whole cell measles virus replication assay, we describe here some aspects of the iterative process that, from 2-(4-benzyl-3-ethoxy-5-methyl-1H-pyrazol-1-yl)pyrimidine, led to 2-(4-(2,6-difluorophenoxy)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)-5-ethylpyrimidine and a 4000-fold improvement of antiviral activity with a subnanomolar level of inhibition. Moreover, recent precedents in the literature describing antiviral derivatives acting at the level of the de novo pyrimidine biosynthetic pathway led us to determine that the mode of action of this series is based on the inhibition of the cellular dihydroorotate dehydrogenase (DHODH), the fourth enzyme of this pathway. Biochemical studies with recombinant human DHODH led us to measure IC50 as low as 13 nM for the best example of this original series when using 2,3-dimethoxy-5-methyl-6-(3-methyl-2-butenyl)-1,4-benzoquinone (coenzyme Q(1)) as a surrogate for coenzyme Q(10), the cofactor of this enzyme.
• Synthesis of S2-Alkyl-2-thiouridines
  作者：Adel A.-H. Abdel-Rahman、Magdy A. Zahran、Ahmed E.-S. Abdel-Megied、Erik B. Pedersen、Claus Nielsen

  DOI：10.1055/s-1996-4187

  日期：1996.2

  5-Substituted S 2-alkyl-2-thiouracils 1a-i were treated with 1,1,1,3,3,3-hexamethyldisilazane and ammonium sulfate at reflux temperature and condensed with 1,2,3,5-tetra-O-acetyl-β-D-ribufuranose in acetonitrile using trimethylsilyl trifluoromethanesulfonate as a catalyst to afford the corresponding protected nucleosides 2a-i which were deprotected with saturated ammonia in methanol. When the nucleobase was substituted with ethoxycarbonyl or cyano groups in the 5-position or was unsubstituted, the deprotection reaction of the nucleoside also resulted in replacement of the methylthio group. This was not observed with 5-alkyl and 5-methoxy substituents.

  5-取代的S 2-烷基-2-硫脲嘧啶1a-i与1,1,1,3,3,3-六甲基二硅氮烷和硫酸铵在回流温度下反应，然后在乙腈中与1,2,3,5-四-O-乙酰基-β-D-核呋喃糖缩合，使用三甲基硅基三氟甲磺酸作为催化剂，得到相应的保护核苷2a-i，这些核苷随后用甲醇中的饱和氨进行去保护。当核碱基在5位上被乙氧羰基或氰基取代或不取代时，核苷的去保护反应也会导致甲硫基团的替换。对于5-烷基和5-甲氧基取代基，则没有观察到这种现象。